The preparation and characterization of alkaline phosphatase-thyroxine conjugates and their use in the enzyme immunoassay of thyroxine
Alkaline phosphatase from calf intestine was conjugated to thyroxine using cyanuric chloride, glutaraldehyde and l-cyclohexyl-3( -2 morphoinoethyl)carbodiimide as coupling reagents. The conjugates produced were studied for incorporation of thyroxine, retention of enzyme activity and immunoreactivity in a thyroxine radioimmunoassay system against a range of thyroxine antisera. The use of these conjugates in thyroxine enzyme immunoassay was studied using second-antibody separation. Comparison of the results with radioimmunoassay data was satisfactory and indicates the potential of these conjugates for thyroxine immunoassay. The use of cyanuric chloride as a coupling reagent was unsatisfactory, but good results were obtained with glutaraldehyde. Although satisfactory immunoreactivity of carbodiimide conjugates was observed in a radioimmunoassay system, these results were not reflected in the enzyme immunoassay systems studied.
The introduction of enzyme labels into clinical chemistry has provided an effective alternative to isotopic labels such as 12'1 for immunoassay systems. l. 2. :1 The use of 12'1 labels is associated with a well understood and highly developed chemistry." but the problems associated with enzyme labels have not been so extensively studied, particularly with low molecular weight antigens.
The ultimate sensitivity and specificity of the immunoassay system resides in properties of the antibody-antigen reaction. The function of the label in the system is to allow the properties of the antibody to be expressed fully. In the preparation of enzyme conjugates for immunoassays the immunoreactivity of the prepared conjugate is of prime importance; any reduction will cause the potential of the system to be limited. Similarly the specific activity of the enzyme and the levels at which it can be conveniently and precisely measured are important factors. The criteria of desirability of enzymes for use in enzyme immunoassay have already been reviewed.' With these in mind we Correspondence: I Laing. 434 decided to study alkaline phosphatase conjugates of the small molecule thyroxine, with a view to developing a clinically useful enzyme immunoassay.
Since this work began, several enzyme immunoassay systems for thyroxine have appeared in the literature. Much of the work has come from commercial organisations and in some cases published information has been incomplete. In 1975 the Syva Corporation introduced a homogeneous enzyme immunoassay for thyroxine which was not explained in detail until 1979.'" 7 This assay system made use of malate dehydrogenase from pig heart. Albert et al.K working for the Boehringer Corporation described a coated-tube enzyme immunoassay system for thyroxine using horseradish peroxidase. The same enzyme was used by Schall et al.Y in the same year working for the Organon Diagnostics Corporation. These workers used a solid-phase separation system based on antibody covalently coupled to aminated latex particles. An additional enzyme label (~ galactosidase) has been described for thyroxine immunoassay incorporating a solid-phase column chromatographic separation of free and bound label. III Whilst a variety of enzymes have been used, only one homogeneous system has been described. Most workers have characterised their enzyme labels in terms of thyroxine covalently coupled to the enzyme; with one exception." retention of enzyme activity has not been discussed. Attempts to assess the immunoreactivity of the prepared conjugates have not been made.
We describe here the preparation of conjugates of thyroxine with calf intestine alkaline phosphatase in which the incorporation of ligand, retention of enzyme and immunoreactivity of the incorporated ligand are studied. The use of these conjugates in thyroxine enzyme immunoassay systems is described, and the results obtained are compared with a reference radioimmunoassay. Our findings are relevant to the development of enzyme immunoassay systems for small molecules.
Materials and methods
Single-distilled water was used in these studies, All buffer solutions were prepared from AR grade chemicals. The following reagents were obtained from the Sigma Chemical Co: alkaline phosphatase types I and 7, specific activities I IU/mg and 1000 IU/mg; thyroxine sodium salt; 8-anilino-naphthalene sulphonic acid; Freund's complete adjuvant; and bovine serum albumin (RIA grade). Sephadex G-2s medium and G-200 fine were obtained from Pharmacia Fine Chemicals. Cyanuric chloride (2,4,6trichloro-I ,3,5-triazine) and l-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-ptoluene sulphonate (sodium salt) were obtained from Aldrich Chemical Co. Glutaraldehyde solution (25'X, w/v in water), and p-nitrophenyl phosphate disodium salt were obtained from Koch-Light Chemicals, Ltd. Polyethylene glycol 6000 was obtained from Hopkins and Williams Ltd. Thyroxine labelled with 125 1 to a specific activity of 20-50 IlCi/llg was purchased from Amersham International. Anti-rabbit precipitating serum (RD 17) and anti-sheep precipitating serum (RD 27) raised in donkeys were obtained from Burroughs Wellcome Ltd. Potassium borohydride was obtained from BDH Ltd.
Clear polystyrene tubes IOx6·5 mm (LP 3 tubes) were obtained from Luckham Ltd. A refrigerated centrifuge Mistral M6L (MSE Ltd) was employed. Samples were counted in a Multigamma 1280 (LKB Ltd). Ultrafiltration apparatus and accessories were supplied by Thyroxine enzyme immunoassay 435 Amicon Corporation. A Pye-Unican SPsOO spectrophotometer with digital read-out attachment was used for absorbance measurement.
Details of the species, sources and immunogens used for the thyroxine antisera in this study are given in Table I . Antisera 7 and 8 were raised in New Zealand white rabbits of the Manchester University strain. Antiserum 7 was the best bleed obtained when four rabbits were immunised with a cyanuric chloride conjugate of type I alkaline phosphatase, prepared as described for high specific activity type 7 alkaline phosphatase, mentioned in detail below. The molar incorporation of thyroxine in this conjugate was estimated to be 15 per mol of protein assuming a molecular weight for the protein of 100 000 daltons. Injections of 55 ug of conjugate expressed as incorporated thyroxine were given. divided over four subcutaneous sites on the back in Freund's complete adjuvant weekly, for 7 weeks. The animals were rested for a further 7 weeks and immunised similarly for a further 4 weeks. The antiserum was obtained by bleeding 1 week after the final injection. Antiserum 8 was the best bleed from four rabbits immunised with a cyanuric chloride bovine serum albumin thyroxine conjugate estimated to contain 14 mol of thyroxine per mol of protein. Later in the schedule the immunogen was changed to a carbodiimide conjugate of the same protein. prepared as alkaline phosphatase conjugate V outlined below, estimated to contain 2·2 mol of thyroxine per mol of protein. The animals were given 12 single-site injections of 60 Ilg bovine serum albumin conjugate in Freund's complete adjuvant at weekly intervals followed by resting for 4 months. After this time the animals were boosted with 120 ug of the carbodiimide conjugate and bled I month later. Freund's complete adjuvant was used for all injections.
PREPARATION OF THYROXINE CONJUGATES

OF ALKALINE PHOSPHATASE
Alkaline phosphatase with high specific activity was supplied as an ammonium sulphate suspension. Before use it was dialysed against the buffer used in the condensation reaction. A molecular weight of lOO ODD was assigned for this material. Conjugate I was prepared from 50 nmol of alkaline phosphatase in 2·2 mL carbonate-bicarbonate buffer pH 9·3; to this was added 6·25 urnol of thyroxine in 2 mL of O·OIM NaOH which contained 100 ODD cpm of labelled thyroxine. A solution of cyanuric chloride (13·6 urnol in 200 III dioxan) was added with rmxing in eight aliquots of 25 ul.; The mixture was incubated at room temperature for 25 minutes and the reaction allowed to continue for a further 48 hours at 4°C. The products were dialysed against carbonate-bicarbonate buffer, pH 8·3, for a further 48 hours at 4°C. A volume of 4 mL from the non-diffusible residue (6 mL) was applied to a column of Sephadex G-25 (40x2·5 m) and the column eluted with 0·1 M carbonate buffer, pH 8·1. Parts of the column eluate were analysed for radioactivity and alkaline phosphatase activity. The fractions containing both enzyme activity and radioactivity were pooled and made up to 30 mL with buffer in which they were stored at 4°C until required. Conjugate II was prepared as above, except that 16 urnol of cyanuric chloride was used and the reaction was carried out for 1 hour, after which it was terminated by the addition of 200 ul, of 1 M L-lysine solution and incubated for 45 minutes. Thereafter the products were treated as the previous preparation. Glutaraldehyde was used as coupling agent for the preparation of conjugates III and IV. For the preparation of conjugate III 37·5 nmol of enzyme in 3 mL of bicarbonate buffer, pH 9·1, was added to 12 mL of 0·(J4 Mbarbitone buffer, pH 9·4. To this solution was added 3·75 urnol thyroxine in 2·5 mL 0·01 M sodium hydroxide followed by 2·5 urnol glutaraldehyde in 50 ul, of water. After 2·5 hours at room temperature 20 urnol L-lysine solution were added in 200 ul, of water followed 1 hour later by the addition of 3·75 umol of potassium borohydride in water and further incubation at O°C for 1 hour. After dialysis of the product against 0·04 Mbarbitone buffer, pH 9-4 (2 L), the sample was concentrated by ultrafiltration and subjected to successive chromatography on a 40x2·5 cm column of Sephadex G-25 twice followed by chromatography on Sephadex G-200. The final chromatogram was eluted with 50 mM Tris buffer, pH 8·2. After identification of the conjugate in the final eluate the residue was again concentrated by ultrafiltration to a volume of 6·5 mL which was then made up to 13 mL with water containing 2 g/L gelatin and 2 rJL sodium azide, and stored at 4°C until required. Conjugate IV was prepared as above except that the purification included an additional Sephadex G-25 chromatographic purification. The final eluate was reduced to a volume of 10 mL and made up to 20 mL with gelatin azide solution as above. From this 5 mL were stored at 4°C and the residue stored in 100 ul, aliquots deep frozen at -200C. For conjugate V a carbodiimide condensation was employed. To 2·5 umol thyroxine in 2 mL 0·01 Msodium hydroxide were added 5·2 urnol of 1-cyclohexyl-3-(2morpholinoethyl) carbodiirnide metho-ptoluene sulphonate sodium salt (solid). The contents were shaken until the solid had dissolved. thea incubated for 3 minutes with continuous mixing. To the mixture was added 3·5 mL of a solution of alkaline phosphatase (20 nmol) in 0·1 M carbonate buffer. pH 9·1. The reaction was allowed to take place for 5 hours at room temperature and the mixture was dialysed against (J·04 M barbitone buffer, pH 9·4 (1 L). overnight. Column purification of this conjugate was carried out as described for conjugate IV and the final product stored at 4°C after the addition of III mL of III g/L bovine serum albumin, containing I giL magnesium chloride and III g/L sodium azide.
For all conjugates. aliquots were taken after each step in the purification for analysis of enzyme activity and radioactivity.
THE RADIOIMMUNOASSAY OF THYROXINE
Thyroxine radioimmunoassay was carried out using double antibody and polyethylene glycol separation procedures. To each LP3 tube was added standard or sample (50 ul.) followed by 400 ul, of O·(JS M phosphate buffer. pH 7 -4, containing H-anilino-naphtha\enesulphonic acid (16(J ug) and radio-labelled thyroxine (0·5 pmol). Standards were prepared by adding thyroxine to charcoal-stripped human serum. Diluted antibody (50 ul.) was then added and incubation carried out at 37°C for 2 hours. A solution of polyethylene glycol (IHO g/L) in I mL distilled water was added, and the tubes were mixed thoroughly followed by centrifugation at 2000 g for 40 minutes. The supernatants were aspirated and the tubes counted. Total activity tubes were also included, and non-specific binding was assessed by substituting 50 ul, of buffer for diluted antibody. All tubes were processed in duplicate. Results were calculated from a manual plot of counts versus concentration.
When second-antibody separation was employed, diluted anti-species second antibody (sheep or rabbit as appropriate) was added in 50 ul, of buffer followed by incubation for lH hours at 4°C. One mL of phosphate buffer was added prior to centrifugation and aspiration as above. Various dilutions of individual antisera were studied to ascertain which were appropri-Thyroxine enzyme immunoassay 437 ate for use in the clinical range. When secondantibody separation was used, each individual dilution of every antiserum used was optimised in the system with various dilutions of the appropriate species-specific second antibody. The range of standards employed in the radioimmunoassay', studies and the subsequently described enzyme immunoassay studies was 0, 18·75, 37·5; 75, 150 and 300 nmoVL.
Varying amounts of each conjugate with respect to the mass of incorporated thyroxine were assayed in the radioimmunoassay system for thyroxine based on polyethylene glycol separation. Dose-response curves were prepared, and the mass of incorporated thyroxine producing 30% displacement of the thyroxine label was determined. This was compared with the mass of standard thyroxine producing the same displacement of radio-label at the same dilution of each antiserum studied. Dilutions of the conjugates for assay were made in 0·05 M phosphate buffer. Each duplicate assay tube contained 50 ul, of charcoal-stripped serum and H-anilino-naphthalene sulphonic acid (160 ug), Conjugates I and II were tested against a limited range of antisera, and conjugates Ill, IV and V were tested against eight antisera.
Comparison of conjugate immunoreactivity was assessed at 30% label displacement instead of 50% displacement which is conventional. This was because certain conjugates were not available in sufficient quantity to permit the addition of amounts which would achieve a 50'Yo label displacement.
MEASUREMENT OF ALKALINE
PHOSPHATASE ACTIVITY
An adaptation of the method of Bowers and McComb l 1 was chosen which uses pnitrophenyl phosphate as substrate. Reagents were prepared as described by these authors except that a substrate concentration of 0·146 mM was employed. Samples of pure alkaline phosphatase or samples from enzyme immunoassays were incubated in 500 JLL of buffer substrate for 30 minutes at 37°C before stopping the reaction with 1·5 mL of 2 M sodium hydroxide. Pure enzyme in the range 0·01 to 0·1 prnol was measured under these conditions. In the range 0·1 to 1·0 pmol the incubation was curtailed to 5 minutes. whilst for the range of enzyme 1-10 pmol the same conditions were used but the products diluted tenfold prior to reading with sodium hydroxide. All standards and samples were read at 402 nM against a reagent blank. The effects of barbitone buffer and 8-anilino-naphthalene sui phonic acid on the activity of 0·1 pmol of underivatised enzyme were investigated at the conditions used in column purification and in the enzyme immunoassay procedures. ENZYME IMMUNOASSAY OF THYROXINE Thyroxine enzyme immunoassays were carried out as described for thyroxine radioimmunoassay using double-antibody separation, except that an additional washing step of the precipitates was carried out prior to determination of enzyme activity. Because phosphate buffer produces product inhibition of alkaline phosphatase activity, this washing step was carried out using Tris buffer. The non-specific binding was estimated in the same way as that described for the radioimmunoassay. After the final centrifugation and aspiration the enzyme activity in the second antibody precipitates was determined as described above. All conjugates were studied at antiserum dilutions used in the radioimmunoassay studies. Conjugates I and II were not studied due to the extremely low immunoreactivity of the thyroxine incorporated into their structures. Conjugates III. IV and V were studied with antisera 1,3.4.5,6 and 8 respectively. The amount of conjugate used in these experiments expressed as mol of incorporated thyroxine was 0·95 pmol for conjugate III, 0·88 pmol for conjugate IV and 0·84 pmol with respect to conjugate V. For experiments carried out with conjugate IV, total enzyme activity tubes were also included. Conjugate III was tested in enzyme immunoassay systems using a variety of dilutions of antiserum I.
MEASUREMENTOFTHYROXINEIN
PATIENTS' SERUM BY ENZYME IMMUNOASSAY Thyroxine levels in patients' serum were measured by enzyme immunoassay using conjugate III. A total of 27 sera were studied and the thyroxine levels determined by radioimmunoassay. A further 104 sera were studied using conjugate IV as label. An additional 18 samples selected for high endogenous levels of alkaline phosphatase ranging from 318 to 897 lUlL were analysed. Antiserum 1 was used for these studies. For the sera with high alkaline phosphatase levels, individual estimates of non-specific binding were made. and the results compared with the values obtained using the standard non-specific binding.
Results
From the results of enzyme activity studies and recovery of thyroxine following column chromatography on Sephadex G-25. conjugate I was estimated to contain 23 mol of thyroxine per mol of enzyme. Of the starting enzyme 47'X, was recovered. In the case of conjugate II the figures were 50 mol of incorporated thyroxine and 52% enzyme activity recovered. For conjugate III 19'Yu of enzyme activity was recovered in the first column eluate giving a T. to enzyme ratio of 0·14. Subsequent chromatography gave results of 0·12 and 0·11. The elution volume of the conjugate on G-200 gave an estimated molecular weight of the conjugate of I III 000 daltons, indicating that enzyme to enzyme coupling had not occurred. In conjugate IV the first column chromatography gave a molar ratio of thyroxine to enzyme of 1·29 on the first purification on G-25. with subsequent values of 0·99,0·70 and 0·60. The final purification was Sephadex G-200, again giving an estimated conjugate molecular weight of 110 000 daltons. Recovery of enzyme activity after the first column purification was 93%. For conjugate V the recovery after the first column was 83%, with subsequent purification as conjugate IV. giving results for molar incorporation of thyroxine into enzyme of 4·2.2·7.2·3 and 2·1. Again the estimated molecular weight of the conjugate from G-200 chromatography was 110 (JOO daltons.
Non-covalent coupling of thyroxine as estimated by G-25 chromatography was estimated to be 0·017. 0·185 and 0·43 at molar excesses of thyroxine of 20, 100 and 125. When enzyme and ligand were chromatographed twice at 100fold molar excess of thyroxine, the estimated coupling ratio was 0·06.
The characteristics of the radioirnrnunoassays for thyroxine in terms of sensitivity at 30% label displacement are given in Table 2 for the various systems optimised with different antisera. They refer to results obtained with polyethylene glycol separation. In general, similar though slightly more sensitive results were obtained when second-antibody separation was employed. The cross-reactivity of the enzyme conjugates produced in terms of incorporated thyroxine are also given in Table 2 , again based on systems with polyethylene glycol ment of enzyme activity in the zero standard is given in Table 3 . The figures were obtained after subtraction of non-specific binding from each standard value. Specific binding of conjugate V to antiserum in the zero standard ranged from 26% with antiserum 5 to 37% with antiserum I expressed as a percentage of the total enzyme activity added. Non-specific binding expressed as a percentage of the total enzyme activity in studies with conjugate IV ranged from 4% to 9,2°/.,. When expressed as percentage of binding to the zero standard with conjugate IV this ranged from II % with antiserum 8 to 30% with antiserum 6. Comparative figures from conjugate III were 14% with antiserum 8 and 8·2'}'0 with antiserum 5. Significant binding of enzyme activity with conjugate V was only obtained with antiserum 8. The effect of various dilutions of antiserum 1 with conjugate IV are shown in Fig. 3 . Enzyme immunoassay results obtained on 27 patients' sera were compared with radioimmunoassay results using polyethylene glycol separation. Regression analysis of the results gave y= 1·004x+ 3·3 (where y=enzyme immunoassay) when double-antibody radioimmunoassay was compared (r=()'949) and y= 1·(XlOx+5·40 when polyethylene glycol separation radioimmunoassay was used (r=0·97). The enzyme immunoassay system employed antiserum I and conjugate III. A further set of comparisons was done in antiserum 1 with conjugate IV and polyethylene glycol radioimmunoassay. The regression analysis gave the following results y=0·911x+ 12·7, (r=0·893). An additional 18 sera selected for high alkaline phosphatase levels gave no significant difference in this enzyme immunoassay system when values obtained using the standard non-specific binding and that from the individual sample were used in the calculation of results (paired r-test: (=1·14, P>0·2) .
Assessment of conjugate III after 5 months' storage at 4°C showed no significant loss of either enzyme activity or immunoreactivity. Storage of conjugate IV for 11 weeks at -10°C showed similar results .
Discussion
The usefulness of alkaline phosphatase as a labelling enzyme for the immunoassay of thyroxine has been demonstrated by the work described here. High retention of enzyme activity was obtained using a range of conjugation procedures and when high levels of molar ---.... <, <, "<, incorporation were achieved. The separation methods used to remove unreacted starting material were shown to be highly effective. This is important as unreacted thyroxine will react with antibody in subsequent immunoassay systems, thereby diminishing the performance of the conjugate in those systems. Self-coupling of enzyme could have occurred with any of the conjugation procedures used. In the case of glutaraldehyde and carbodiimide conjugation procedures. Sephadex G-200 chromatography indicated that this did not take place. The incorporation of thyroxine into the enzyme conjugates was based on the recovery of labelled thyroxine during the purification procedure and the residual enzyme activity. Whereas the former can be determined with certainty, the latter represents enzyme mass only if no change in activity is found on coupling. The coupling yields quoted for the various conjugates are therefore approximations as enzyme mass was not determined. In addition, non-enzyme impurities may affect the results obtained. The high purity of the enzyme used for conjugation purposes has already been demonstrated.V
The colorimetric procedure described for the assay of alkaline phosphatase demonstrated sufficient sensitivity for the purpose required. A fluorimetric assay would have produced much more sensitivity if needed. The colorimetric procedure described does not provide as sensitive a detection system as the more usually employed 125 1 labels for thryoxine immunoassay.
When a conjugate is produced for use in an enzyme immunoassay, optimal assay performance will be achieved when the enzyme activity is retained and the immunoreactivity of the molecule to which it is coupled is also retained. We assessed the immunoreactivity of incorporated thyroxine in the conjugates produced to investigate the latter point. The results from cyanuric chloride condensations indicate that at the level of coupling achieved with this reagent extremely low immunoreactivity of incorporated thyroxine was encountered. The use of glutaraldehyde and carbodiimide conjugation procedures resulted in much improved immunoreactivity, the former giving the better results. For all conjugates the immunoreactivity was extremely antiserum dependent. Whilst the highest immunoreactivity was achieved at low coupling yields with glutaraldehyde, the use of conjugates with coupling yields of significantly less than unity with respect to ligand results in the presence of unreacted enzyme in the conju-Thyroxine enzyme immunoassay 441 gate preparation. This is expressed as 'noise' in enzyme immunoassay systems and can be dealt with only if efficient systems are employed for the separation of antibody-bound label. When coupling ratios of greater than unity are used the effective specific activity of the ligand is reduced, which decreases the level at which it can be measured. In terms of coupling yields alone the present study indicates that low coupling yields produce the most reactive conjugates. This must be interpreted in the light of the different bridge linkages employed. When the same bridge linkage was used (glutaraldehyde) higher immunoreactivity was achieved with the lower degree of coupling. These observations may reflect steric effects relating to the protein at the part of reaction with the ligand. In conditions where incorporation yields are limited it is likely that sterically favoured groups in the protein are more reactive. This might be reflected in the subsequent immunoreactivity of the resulting conjugate. The importance of steric effects may also be inferred by comparison of the immunoreactivity of the glutaraldehyde conjugates with the carbodiimide conjugate. The latter in combination with four antisera used (1,2,3 and 6) represents a homologous bridge system; that is, the bridge used to couple the hapten to the immunisation conjugate is the same as that used in the production of the enzyme label. In contrast, the glutaraldehyde conjugates represent a heterologous bridge system. That is, the bridge used in the preparation of the immunogen is different from that of the conjugate. In the case of all antisera the heterologous bridge systems provide the highest immunoreactivity. This is in direct conflict with results obtained with a variety of steroid conjugates of small molecular weight iodinatable residues, e.g. progesterone and histamine where homologous bridge systems almost invariably produce conjugates of greater immunoreactivity than the unmodified ligand;':' The bridge length for carbodiimide coupling is 0·4 nM and for glutaraldehye is 0·8 nM. Although the bridge structure is dissimilar, the added length of the latter bridge might be expected to minimise steric effects at the protein surface, and permit easier access of the hapten to the antibody-binding site.
Other authors have not commented on the immunoreactivity of incorporated thyroxine in enzyme immunoassay, although conjugation yields of thyroxine have been reported. These vary from I thyroxine to 70 of peroxidase" to 2 per molecule of malate dehydrogenase" and 4 with~-galactosidase.III In the case of malate dehydrogenase, retention of enzyme activity was relatively high (20%) and the type of system employed (homogeneous assay) requires a highly immunoreactive conjugate. The use of a solid-phase system for separation with a washing step was employed with peroxidase label, but the immunoreactivity of the conjugate was not assessed. Y When B-galactosidase was employed as label a solid-phase system was also employed. III Clearly the properties of the conjugate are important when considering the separation procedure. Useful results can be obtained with conjugates of varying degrees of substitution and immunoreactivity depending on the efficiency of the separation procedure. When the degree of substitution is optimal. approximately unity. and the immunoreactivity of the conjugate is high, versatile systems may be developed.
The enzyme immunoassay systems described present some interesting features. They were performed using what is considered an efficient separation system, that is. double-antibody separation with a washing step. They were set up using the same antibody dilutions as the radioimrnunoassays for each antiserum studied. It is clear that antiserum I gave a dose-response more appropriate to the clinical range with conjugate III than conjugate IV. This was reflected in the better agreement of patient samples with the reference method using the former conjugate. The fact that with conjugate IV high levels of endogeneous enzyme activity in serum did not affect the results was probably due to the efficient separation procedure. It is considered that conjugate III gave a more useful clinical assay but that the system involving conjugate IV could have been better optimised by manipulation of antibody dilution. Indeed systems of greater potential were available for both conjugates using different antisera. A further drawback of conjugate IV compared with conjugate III was the higher level of non-specific binding assessed for comparison with conjugate III by the ratio of non-specific binding to the enzyme activity in the zero standard. This was higher in the latter case. and is an important point in the performance of any immunoassay system as high non-specific binding attenuates the slope of the dose-response curve thus reducing available precision. In all systems conjugate III gave more sensitive enzyme irnmunoassays than conjugate IV. although the immunoreactivity of incorporated ligand in the conjugates was similar. In the case of conjugate V. however. useful immunoassay results were obtained with only one antiserum studied in spite of appreciable immunoreactivity of incorporated thyroxine with all antisera studied. As this conjugate was prepared with high retention of enzyme activity. which remained associated with thyroxine after extensive purification. these results are difficult to explain. However. it must be remembered that reaction of an enzyme-hapten conjugate with an anti-hapten antibody can cause a change in the activity of the enzyme.!" This is a possible explanation for the results obtained with conjugate V although this was not verified by direct experiment. Inhibition of enzyme activity by reaction with hapten antibody is amplified when the bridge linkage employed is short. This is the case with conjugate V. This effect provides the basis of homogeneous enzyme immunoassay systems.
The sensitivity of enzyme immunoassays set up with conjugate III was greater than those using conjugate IV at the same antiserum dilutions. Sensitivity of assays with conjugate III approached those available with 125 1_ labelled thyroxine with some antisera. Although useful enzyme immunoassay systems were developed. the properties of these systems depend to a great extent on the enzyme conjugate used as label. In addition, selection of antiserum appears important in terms of assay sensitivity. The systems described appear less versatile than those available with radioiodinated thyroxine.
